secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0000950170-24-090722
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta reports Q3 net loss $22.7M, cash $272.6M; RSV trials on track
--------------------------------------------------------------------

- Revenue $18.0M (royalty from AbbVie's MAVYRET); net loss $22.7M ($1.07 EPS) vs $39.1M loss a year ago.
- Cash, equivalents and securities $272.6M at June 30, 2024; expects runway through Q3 FY2027.
- Completed enrollment in RSVPEDs Phase 2 study of zelicapavir in pediatric RSV; topline data expected Q4 2024.
- EDP-323 Phase 2a challenge study completed; topline data expected late Q3 2024.
- Legal expenses increased due to patent infringement lawsuit against Pfizer; no Q3 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017024090722/0000950170-24-090722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017024090722/enta-20240805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-090722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer